Unity Bio Calls Special Meeting for Dissolution Vote

TL;DR

**Unity Bio is likely dissolving, get out now if you haven't already.**

AI Summary

Unity Biotechnology, Inc. is holding a Special Meeting of Stockholders on September 18, 2025, at 9:00 a.m. Pacific Time, to be conducted virtually. The primary purpose of this meeting is to vote on a 'Dissolution Proposal,' indicating a potential strategic shift or wind-down of operations. Stockholders of record as of July 25, 2025, for both common stock and Series A Preferred Stock, are eligible to vote. The Series A Preferred Stock is specifically limited to voting only on the Dissolution Proposal. The company, incorporated in Delaware, operates in the pharmaceutical preparations sector. While specific revenue and net income figures are not provided in this DEF 14A, the focus on a dissolution proposal suggests significant financial or operational challenges, or a strategic pivot away from its current structure. The filing emphasizes the importance of stockholder participation, urging prompt voting via proxy card, Internet, or telephone.

Why It Matters

This DEF 14A filing signals a critical juncture for Unity Biotechnology, Inc., as the 'Dissolution Proposal' could lead to the company's wind-down, significantly impacting investors' equity value. For employees, it raises immediate concerns about job security and the future of their work in the pharmaceutical preparations sector. Customers and partners relying on Unity's pipeline or existing products would need to assess continuity plans. In the competitive biotech landscape, a dissolution could free up talent and resources, potentially benefiting rival firms, while also highlighting the inherent risks and high failure rates in drug development.

Risk Assessment

Risk Level: high — The filing explicitly states a 'Dissolution Proposal' will be voted on at the Special Meeting on September 18, 2025. This indicates a high probability of the company ceasing operations, which would result in significant, if not total, loss of investment for stockholders. The Series A Preferred Stock's voting rights are specifically limited to this proposal, underscoring its gravity.

Analyst Insight

Investors should immediately review their holdings in Unity Biotechnology, Inc. and consider divesting, given the explicit 'Dissolution Proposal.' Those holding Series A Preferred Stock should ensure their vote is cast on the dissolution, as it directly impacts their investment's future.

Key Numbers

• 2025-09-18 — Special Meeting Date (Date when stockholders will vote on the Dissolution Proposal)
• 2025-07-25 — Record Date (Date determining stockholders eligible to vote at the Special Meeting)
• $0.0001 — Par Value per Share (Par value for both common stock and Series A Preferred Stock)

Key Players & Entities

• Unity Biotechnology, Inc. (company) — Registrant and subject of the DEF 14A filing
• September 18, 2025 (date) — Date of the Special Meeting of Stockholders
• July 25, 2025 (date) — Record date for stockholders entitled to vote
• Delaware (regulator) — State of incorporation for Unity Biotechnology, Inc.
• 0001463361 (regulator) — Central Index Key (CIK) for Unity Biotechnology, Inc.
• 285 East Grand Avenue (company) — Business address for Unity Biotechnology, Inc.
• South San Francisco (company) — City of Unity Biotechnology, Inc.'s business address
• $0.0001 (dollar_amount) — Par value per share for common stock and Series A Preferred Stock
• 9:00 a.m. Pacific Time (date) — Time of the Special Meeting of Stockholders
• www.virtualshareholdermeeting.com/UBX2025SM (company) — Virtual meeting platform for Unity Biotechnology, Inc.'s Special Meeting

FAQ

Risk Factors

• Potential Dissolution of Operations [high — financial]: The company is proposing a Dissolution Proposal at the Special Meeting on September 18, 2025. This indicates a significant strategic shift, potentially involving the wind-down of operations, which could result in a loss of investment for shareholders.

Industry Context

Unity Biotechnology operates within the pharmaceutical preparations sector, a highly competitive and research-intensive industry. Companies in this space focus on developing and commercializing novel therapeutics, often facing long development cycles, significant regulatory hurdles, and substantial capital requirements. The industry is characterized by innovation in areas like biotechnology, with a constant drive to address unmet medical needs.

Regulatory Implications

As a biotechnology company, Unity is subject to stringent regulations from bodies like the FDA. While this filing focuses on corporate governance and a potential dissolution, any ongoing or past regulatory compliance issues could impact the process. The proposed dissolution itself may also involve specific regulatory steps for winding down pharmaceutical operations.

What Investors Should Do

1. Review the Dissolution Proposal details thoroughly.
2. Vote your shares promptly.
3. Attend the virtual Special Meeting on September 18, 2025.

Key Dates

• 2025-09-18: Special Meeting of Stockholders — Stockholders will vote on the critical Dissolution Proposal, which could lead to the company's dissolution.
• 2025-07-25: Record Date — Determines which stockholders are eligible to vote at the Special Meeting on the Dissolution Proposal.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information about a company's annual meeting of stockholders, including matters to be voted on. (This document is the proxy statement for Unity Biotechnology's special meeting, outlining the proposed dissolution and related voting procedures.)

Dissolution Proposal

A formal proposal put forth to the company's stockholders to approve the dissolution and winding down of the company's operations. (This is the primary and most critical item on the agenda for the Special Meeting, signaling a potential end to the company's current business.)

Series A Preferred Stock

A class of preferred stock that has specific rights and privileges, in this case, limited voting rights solely on the Dissolution Proposal. (Highlights a specific class of shareholders with a defined, albeit limited, role in the company's potential dissolution.)

Par Value

A nominal value assigned to a share of stock, often a very small amount, used for accounting purposes. (Indicates the nominal value of both common and Series A Preferred Stock is $0.0001 per share.)

Year-Over-Year Comparison

This DEF 14A filing is distinct from typical annual reports as it focuses on a Special Meeting and a proposed dissolution. Therefore, a direct comparison of key financial metrics like revenue growth or margin changes to a previous year's filing is not applicable. The primary focus is on the strategic decision regarding the company's future operations rather than ongoing business performance.

Key Financial Figures

• $0.0001 — f record of our common stock, par value $0.0001 per share, and of our outstanding share

Filing Documents

• ny20051823x2_def14a.htm (DEF 14A) — 413KB
• ny20051823x2_pc01.jpg (GRAPHIC) — 558KB
• ny20051823x2_pc02.jpg (GRAPHIC) — 449KB
• 0001140361-25-030046.txt ( ) — 1800KB

RISK FACTORS

RISK FACTORS 3 QUESTIONS AND ANSWERS REGARDING THIS SOLICITATION AND VOTING AT THE SPECIAL MEETING 7 PROPOSAL 1: APPROVAL OF THE DISSOLUTION PURSUANT TO THE PLAN OF DISSOLUTION 14 CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PROPOSED DISSOLUTION 25 PROPOSAL 2: APPROVAL OF ADJOURNMENT OF SPECIAL MEETING TO SOLICIT ADDITIONAL PROXIES 31

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 32 WHERE YOU CAN FIND ADDITIONAL INFORMATION 34 HOUSEHOLDING 35 OTHER MATTERS 36 EXHIBIT A 37 ANNEX A A-1 i TABLE OF CONTENTS CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This proxy statement, including the documents incorporated by reference into this proxy statement, contains forward-looking statements, including within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact contained in this proxy statement are "forward-looking statements" for purposes of this proxy statement. These statements involve known and unknown risks, uncertainties, assumptions and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "target," "predict," "project," "contemplate," "should," "will," "would," "continue" or the negative or plural of those terms or other similar expressions.

Forward-looking statements in this proxy statement include, but are not limited to

Forward-looking statements in this proxy statement include, but are not limited to: plans and expectations for the Dissolution; beliefs about the Company's available options and financial condition; all statements regarding the tax and accounting consequences of the transactions contemplated by the Dissolution; and all statements regarding the amount and timing of distributions made to stockholders, if any, in connection with the Dissolution. The forward-looking statements in this proxy statement are only predictions. We based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Risks, uncertainties and assumptions that may cause actual results to differ materially from current expectations include, among other things, those set forth in under the caption "Risk Factors" in this proxy statement and our 2024 Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"). Any forward-looking statement in this proxy statement reflects our current view with respect to future events, speaks only as of the date of this proxy statement, and is subject to these and other risks, uncertainties and assumptions. Given these uncertainties, you should not rely on these forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, our information may be incomplete or limited and we cannot guarantee future results. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to

RISK FACTORS

RISK FACTORS The following risk factors, together with the other information in this proxy statement and in the "Risk Factors" sections included in the documents incorporated by reference into this proxy statement (see the section entitled "Where You Can Find Additional Information" beginning on page 34 of this proxy statement), should be carefully considered before deciding whether to vote to approve the Dissolution Proposal as described in this proxy statement. In addition, stockholders should keep in mind that the risks described below are not the only risks that are relevant to your voting decision. The risks described below are the risks regarding the Dissolution that we currently believe are the material risks of which our stockholders should be aware. Nonetheless, additional risks that are not presently known to us, or that we currently believe are not material, may also prove to be important. RISKS RELATED TO THE DISSOLUTION We cannot predict the timing of the distributions to stockholders. Our current intention is that, if approved by our stockholders, the Certificate of Dissolution would be filed as soon as reasonably practicable after such approval; however, the timing of such filing and the decision of whether or not to proceed with the Dissolution will be made by the Board in its sole discretion and in its own timing. No further stockholder approval would be required to effect the Dissolution. However, if the Board determines that the Dissolution is not in our best interest or the best interest of our stockholders, the Board may, in its sole discretion, abandon the Dissolution or may amend or modify the Plan of Dissolution to the extent permitted by Delaware law without the necessity of further stockholder approval, pursuant to the Plan of Dissolution. After the Certificate of Dissolution has been filed and becomes effective, revocation of the Dissolution would require stockholder approval under Delaware law. Under Delaware law, before a dissolved c

View Full Filing

View this DEF 14A filing on SEC EDGAR